Identification of a Calcitriol-Regulated Sp-1 Site in the Promoter of Human CD14 using a Combined Western Blotting Electrophoresis Mobility Shift Assay (WEMSA) by Moeenrezakhanlou, Alireza et al.
Biol. Proced. Online 2008; 10(1): 29-35
doi:10.1251/bpo140
February 17, 2008
Identification of a Calcitriol-Regulated Sp-1 Site in the Promoter
of Human CD14 using a Combined Western Blotting
Electrophoresis Mobility Shift Assay (WEMSA)
Alireza Moeenrezakhanlou
1,2, Devki Nandan
1 and Neil E. Reiner
1#
 
1Department of Microbiology and Immunology, University of British Columbia, Faculties of Medicine and Science, and Vancouver Coastal Health Research
Institute (VCHRI), Vancouver, British Columbia, Canada, V5Z 3J5.
2School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
#Corresponding Author: Neil E. Reiner, Division of Infectious Diseases, University of British Columbia, Rm 452D, 2733 Heather Street, Vancouver, BC.
Canada, V5Z 3J5. Phone: 604-875-4011; Fax: 604-875-4013; E-mail: ethan@interchange.ubc.ca
Submitted: March 23, 2007; Revised: December 10, 2007; Accepted: December 12, 2007
Indexing terms: Electrophoretic Mobility Shift Assay; Transcription Factors; Antigens, CD14
Abbreviations: TF, transcription factor; VDRE, vitamin D response element; WEMSA, western blot electrophoretic mobility shift assay
ABSTRACT
Calcitriol (1 , 25-dihydroxyvitamin D ￿ 3) induces the expression of CD14 in mononuclear phagocytes. The mechanisms
accounting for this have been unclear since the promoter of CD14 does not contain a canonical vitamin D response
element (VDRE). Calcitriol has been shown to regulate the activity of the transcription factor Sp-1 and our analysis of
the proximal promoter of CD14 indicated the presence of four Sp-1-like binding sequences. To identify which of these
sites might be involved in the response to calcitriol, we used a system incorporating an electrophoretic mobility shift
assay (EMSA) coupled to Western blot analysis (WEMSA). Using WEMSA, we found that only one of the Sp-1-like
binding sequences, located at position -91 to -79 (relative to the transcription start site), bound the transcription factor
Sp1. Sp-1 binding to this site was demonstrable using nuclear extracts from control cells. Notably, binding activity was
attenuated in nuclear extracts prepared from cells that had been incubated with calcitriol, thus suggesting Sp-1
involvement in calcitriol induction of CD14 expression. Notably, these results show that like EMSA, WEMSA can be
broadly applied to aid in the identification of transcription factors involved in regulating gene expression. WEMSA,
however, offers a number of distinct advantages when compared with conventional EMSA. Antibodies used for
WEMSA often provide less ambiguous signals than those used in EMSA, and these do not have to recognize epitopes
under native conditions. In addition, WEMSA does not require the use of labeled oligos, thus eliminating a significant
expense associated with EMSA. 
INTRODUCTION
The regulation of gene expression in mammalian cells is
controlled by approximately 200 transcription factors that
interact with distinct DNA binding sites (1). Transcription
factors (TF) are proteins involved in the negative and
positive regulation of gene expression. Their mechanisms
of action may involve either direct binding to specific
DNA sequences in promoter regions of target genes, or
indirect effects on gene expression through interactions
with other proteins directly bound to DNA elements. Each
TF is defined by the short DNA sequences that reflects its
DNA  binding   motif   (2).   TFs   usually   consist   of   two
functional   domains,   a   DNA   binding   domain   and   a
regulatory domain that interacts with components of the
transcription initiation complex and regulatory proteins,
thereby   affecting   the   efficiency   of   DNA  binding   and
transcription. Typically, gene promoters contain several
functional TF-DNA binding sites and in most cases, there
is more than one specific DNA binding site for a particular
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TF (3). In addition, promoters of human genes contain
many transcription factor binding elements that have a
varied range of identities when compared to canonical
transcription factor binding elements (4).
Calcitriol induces monocyte differentiation and this is
reflected in increased surface expression of both CD14 and
CD11b (5). Since no canonical vitamin D response element
(VDRE) has been identified in the human CD14 promoter,
the mechanism of CD14 activation in response to calcitriol
is unclear. Recently, the transcription factor CREB has
been shown to be activated by calcitriol and to play a role
in the regulation of CD14 expression (6). It has also been
reported that calcitriol modulates Sp-1 activity and this
too may be involved in regulating CD14 expression (7).
Sp-1 belongs to a family of transcription factors that bind
to GC-rich sequences and is involved in regulating cell
growth, apoptosis and angiogenesis (reviewed in 8). Our
analysis   of   the   proximal   promoter   of   human  CD14
identified four candidate Sp-1-like sequences. This raised
the   question   of   which,   if   any,   of   these   sequences   is
involved in regulating the CD14 response to calcitriol. 
Conventionally,   electrophoretic   mobility   shift   assays
(EMSA) combined with antibody supershifts are used to
investigate the interactions of TFs with specific DNA
elements (9). EMSAs are carried out using short synthetic
labeled   DNA   probes   corresponding   to   TF   binding
sequences in the promoter region of the gene of interest.
These   probes   are   then   incubated   with   crude   nuclear
extracts followed by the electrophoretic separation of the
resulting protein-DNA mixture on a polyacryamide or
agarose gel in a low ionic strength buffer which results in
a   mobility   shift.   In   general,   an   antibody-   mediated
supershift is then used to confirm the identity of the
particular TF involved. In most situations, canonical DNA
probes are used for EMSA analysis. However, variability
in the DNA binding sequences recognized by TF binding
domains may complicate the results. While supershifts
can be highly informative, they have limitations. In many
supershift assays for example, multiple bands are present
which   may   be   diffuse   and   difficult   to   interpret.   In
addition, antibodies capable of mediating a supershift for
a particular transcription factor of interest may not always
be   available   because   of   the   requirement   that   they
recognize epitopes under native conditions (10). The very
nature of the supershift assay itself also does not allow the
re-use   of   antibodies,   thus   making   this   technique
somewhat   costly.   Moreover,   EMSA-based   supershift
assays are carried out in a manner such that they do not
permit examination of multiple TFs simultaneously. In a
previous report, we used a modification of EMSA to
incorporate Western blotting in a combined approach
which we referred to as WEMSA (6). The present study
again utilizes WEMSA to examine the regulation of Sp-1
binding to the promoter region of CD14 in myeloid cells in
response to calcitriol. The findings reported illustrate the
general   applicability   of   WEMSA   to   identify   active
sequences in gene promoters and their cognate DNA
binding proteins. Because Western blotting is incorporated
in this assay, the recycling of antibodies is possible in most
situations and this significantly reduces the cost normally
associated   with   classical   supershift   assays.   Moreover,
suitable   antibodies   for   WEMSA   are   more   generally
available since there is no requirement that they must
recognize epitopes under native conditions. Importantly,
WEMSA also has the advantage of not requiring the use of
labeled oligos needed for EMSA. This along with the
advantages   outlined   above,   makes   this   technique   an
attractive alternative to classical EMSA to study the roles
of transcription factors in regulating gene expression. 
MATERIALS AND METHODS
Reagents and Chemicals
1 ,25-dihydroxyvitamin D ￿ 3 (calcitriol), was obtained from
Calbiochem Corporation (San Diego, CA). RPMI 1640,
Hank’s   Balanced   Salt   Solution   (HBSS),
penicillin/streptomycin, protease inhibitor cocktail, PMSF,
and poly (dI-dC) were purchased from Sigma Chemical
Co.   (St.   Louis,   MO).   Nitrocellulose   membranes   were
obtained   from   Bio-Rad   Laboratories   (Hercules,   CA).
Unlabelled and labelled Sp-1-like oligos for WEMSA and
EMSA were from Invitrogen (Carlsbad, CA). Unlabelled
and labelled canonical Sp-1 oligos were purchased from
Panomics.  Anti-Sp-1   antibody   was   from   Upstate   Cell
Signaling Solutions (Lake Placid, NY). 
Cell Culture
The human promonocytic cell line THP-1 (acquired from
the American Type Culture Collection, Rockville, MD)
was cultured at 37°C / 5% CO2  in RPMI 1640 medium
supplemented with 10% (v/v) heat-inactivated fetal bovine
serum (FBS), penicillin (100 units/ml) and streptomycin
(100  g/ml). For most experiments, prior to use, cells were ￿
washed in HBSS and incubated for 5 h in RPMI/0.5% FBS
for serum starvation. 
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Preparation of Nuclear and Cytoplasmic Fractions
Nuclear and cytoplasmic fractions were prepared based
on a protocol from the Skirball Institute of Biomolecular
Medicine,   NYU   Medical   Center   (6)   with   minor
modifications. Briefly, approximately 2 x 10
7 THP-1 cells
were used per assay and after treatment the cells were
washed twice with HBSS and collected by centrifugation.
Subsequent steps were performed on ice. The cells were
resuspended in 300  l of fractionation buffer (10 mM ￿
HEPES pH 7.9 containing 50 mM NaCl, 0.5 M sucrose, 0.1
mM EDTA, 0.5% Triton-X 100, 1 mM DTT, 10 mM sodium
pyrophosphate, 2 mM NaF, 17.5 mM  -glycerophosphate, ￿
1 mM PMSF and 4  g/ml aprotinin, 2  g/ml pepstatin A, ￿ ￿
and 2  g/ml leupeptin ￿   and incubated on ice for 5 min.
Nuclei were collected at 4500 x g for 5 min at 4°C. Nuclei
were washed and resuspended in 500  l buffer A (10 mM ￿
HEPES pH 7.9 containing 10 mM KCl, 0.1 mM EDTA, 0.1
mM   EGTA,   1   mM   DTT,   1   mM   PMSF,   and  4   g/ml ￿
aprotinin, 2  g/ml pepstatin A, and 2  g/ml leupeptin) ￿ ￿
and pelleted at 4500 x g for 5 min at 4°C. Nuclear pellets
were resuspended in 40  l of buffer B (10 mM HEPES pH ￿
7.9, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1%
IGEPAL,1 mM DTT, 1 mM PMSF, and 4  g/ml aprotinin, 2 ￿
g/ml pepstatin A, and 2  g/ml leupeptin ￿ ￿ ) and mixed by
extensive vortexing over 10-15 min at room temperature.
Tubes   were   kept   cold   by   placing   them   on   ice
intermittently during vortexing. Samples were centrifuged
at   11,600   x  g  for   20   min   at   4°C   and   supernatants
representing crude nuclear extracts were then transferred
to new tubes and adjusted to a final concentration of 10%
glycerol. The aliquots were stored at -70°C. 
Preparation of the Oligonucleotides
The  promoter  of  CD14  was   analyzed  by  TFSEARCH
software  (http://www.cbrc.jp/research/db/TFSEARCH.html)
and   four   different   candidate   Sp-1   sequences   were
identified. Synthesized solutions of sense and antisense
oligonucleotides were prepared at 10  M concentration in ￿
20 mM Tris pH 8.0. Sense and antisense oligos were then
annealed by heating at 95°C for 5 min and cooled to room
temperature for 15 min before storage at -20°C.
Electrophoretic-Mobility Shift Assay
2-5  g of nuclear extract was used for EMSA according to ￿
the manufacturer’s instructions (Panomics, EMSA Gel-
Shift   Kit).   Briefly,   nuclear   extracts   containing   equal
amounts of protein for each sample were incubated with
poly (dI-dC) (1  g/ l) for 5 min, followed by the addition ￿ ￿
of binding buffer (20 mM HEPES pH 7.9, 1 mM DTT, 0.1
mM EDTA, 50 mM KCl, 5% glycerol and 200  g/ml BSA) ￿
and biotinylated oligo (10 ng/ l). To control for specificity ￿
of binding, for selected samples, a 5-fold excess of non-
labeled oligo was added prior to the addition of the
biotinylated   probe.   Binding   reaction   mixtures   were
incubated for 30 min at room temperature. Protein-DNA
complexes   were   separated   on   5%   nondenaturing
polyacrylamide gels in Tris-borate/EDTA buffer (0.1 M
Tris, 0.09 M boric acid containing 1mM EDTA) at 4°C.
After   electrophoresis,   gels   were   transferred   to   nylon
membranes. Transferred oligos were immobilized by UV
crosslinking for 3 min. For detection of bound oligos,
membranes were blocked using blocking buffer (Panomics
EMSA   Gel-Shift   Kit)   followed   by   the   addition   of
Streptavidin-HRPO and blots were developed by ECL
according to the manufacturer’s instructions (Amersham,
Arlington Heights, IL, U.S.A.). Commercially available
biotinylated oligonucleotide encoding the Sp-1 motif 5'-
ATTCGATCGGGGCGGGGCGAG-3'   was   used   as   a
canonical probe (Panomics, AY-1043).
Combined EMSA and Western blotting (WEMSA)
For this assay we used custom synthesized non-labeled,
oligonucleotides encoding the Sp-1-like binding sequences
located within the proximal promoter of  CD14  (Fig. 1).
The   Sp-1-like   oligos   were   as   follows:   (1)   5'-
GGGGGGTTGG-3'   at   position   -345   to   -336,   (2)   5'-
GTCCCTCCCCCT-3'  at   position   -159  to   -148   ,  (3)  5'-
AGGGGGCTGGC-3' at position -113 to -100 and (4) 5'-
AGAGGTGGGGAGG-3' at position -91 to -79 . WEMSA
was performed essentially as described above, with the
exception that separated DNA-protein complexes were
transferred to nitrocellulose membrane instead of nylon
membrane   and   probed   with   anti-Sp-1   for   Western
blotting. Blots were developed by ECL. 
RESULTS AND DISCUSSION
The Screening for Calcitriol-Regulated Binding of Sp-1 to
DNA Response Elements in Human CD14 by WEMSA
In many gene promoters it is possible to find multiple
candidate binding sites for any particular transcription
factor.   Prior   analysis   of   the   human  CD14  promoter
indicated five CRE-like sites (6) and four candidate Sp-1
sites (sequences 1-4 in Fig. 1). These four sites show
70-85% homology with canonical Sp-1-binding sequences.
Using conventional EMSA, four labeled-oligonucleotides
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based on each of these putative sites would have been
required to examine which, if any, were involved in Sp-1
binding. On the other hand, WEMSA does not require
labeling of oligonucleotides as identification of the TF
involved   is   based   on   Western   blotting   using   specific
antibodies.   To   evaluate   further   the   effectiveness   of
WEMSA in screening for candidate DNA binding sites of a
transcription   factor   of   interest,   oligonucleotides   were
synthesized based on the four Sp-1-like sequences in the
human  CD14  promoter. THP-1 cells were treated with
calcitriol   and   nuclear   extracts   were   prepared   and
incubated   with   these   four   Sp-1-like   sequences
independently.   DNA-protein   complexes   were   then
separated by 5% polyacrylamide gel electrophoresis, and
separated DNA-protein complexes were transferred to
nitrocellulose membranes for immunodetection of Sp-1.
The results shown in Fig. 2 indicate that Sp-1 bound to
only one  of  the  four  candidate  Sp-1  sites.  This   Sp-1
binding   site   (5'-AGAGGTGGGGAGG-3')   located   at
positions -91 to -79 within the  CD14  promoter has 85%
identity   to   the   canonical   Sp-1   sequence   (5'-
ATTCGATCGGGGCGGGGCGAG-3'). Sp-1 binding to this
site was apparent in nuclear extracts from cells in the
basal state and binding activity was negatively regulated
by calcitriol. Whereas conventional Western blotting of
nuclear extracts detected the presence of Sp-1 in protein
DNA complexes (Fig. 2), free Sp-1 not bound to DNA was
not detected in the WEMSA assay (data was not shown).
This was as expected since the 5% polyacrylamide gel
would be unlikely to retain proteins of relatively smaller
molecular mass such as uncomplexed free Sp-1. As an
additional   test   for   calcitriol-regulated   Sp-1   binding
activity, we conducted a parallel WEMSA analysis, in
which the candidate Sp-1-like oligo from  CD14  and a
canonical Sp-1 oligo were used in parallel. Sp-1 binding to
both the candidate and canonical sequences displayed
similar activities in control and calcitriol-treated THP-1
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Fig. 1: CD14 proximal promoter. This region spanning 469 bp
upstream of the transcriptional start site has been shown to be critical for
the induction of CD14 transcription in response to calcitriol. Putative Sp-1-
like transcription factor-binding sites in this region were identified using the
TFSEARCH program (http://www.cbrc.jp/research/db/TFSEARCH.html) and
are highlighted in boldface, underlined and labeled as (1) 5'-
GGGGGGTTGG-3' at position -345 to -336, (2) 5'-GTCCCTCCCCCT-3' at
position -159 to -148 , (3) 5'-AGGGGGCTGGC-3' at position -113 to -100 and
(4) 5'-AGAGGTGGGGAGG-3' at position -91 to -79. 
-469  
AGTTAAATATCTGAGGATATTCAGGGACTTGGATTTGGTGGCAGGAGATCAA 
 
CATAAACCAAGACAAGGAAGAAGTCAAAGAAATGAATCAAGTAGATTCTCT 
    
GGGATATAAGGTAGGGGGATTGGGGGGTTGGATAGTGCAGAGTATGGTATG 
                                                    -345     Sp-1 (1)     -336 
GCCTAAGGCACTGAGGATCATCCTTTTCCCACACCCACCAGAGAAGGCTTAG 
                  
GCTCCCGAGTCAACAGGGCATTCACGCCTGGGGCGCCTGAGTCATCAGGACA 
                                                                                  
CTGCCAGGAGACACAGAACCCTAGATGCCCTGCAGAATCCTTCCTGTTACGG 
                                                                                                                                  -159 
TCCCCCTCCCTGAAACATCCTTCATTGCAATATTTCCAGGAAAGGAAGGGGGC 
      Sp-1 (2)     -148                                                                                           -113   Sp-1 (3)  
TGGCTCGGAGGAAGAGAGGTGGGGAGGTGATCAGGGTTCACAGAGGAGGGA 
          - 100                   -91     Sp-1 (4)                -79            
ACTGAATGACATCCCAGGATTACATAAACTGTCAGAGGCAGCCGAAGAGTT 
 
CACA -1 
Fig. 2: WEMSA shows that Sp-1 binding to a specific site in the
CD14 promoter is regulated by calcitriol. Serum starved THP-1 cells
were either treated or not with 100 nM calcitriol for 30 min followed by
preparation of nuclear extracts for WEMSA as described in Materials and
Methods. Nuclear extracts were incubated with four unlabelled oligos
denoting putative Sp-1-like transcription factor-binding sites in CD14
promoter (A) and DNA protein complexes were separated by non-denaturing
gel electrophoresis followed by transfer to nitrocellulose for Western
blotting for Sp-1 (B). The results shown are from one of three independent
experiments that yielded similar results.
A.  Sp-1-like oligos  
 1. 5’-GGGGGGTTGG 
             2.  5’-TCCCCCTCCCT   
            3.  5’-GGGGGCTGGC 
            4.   5’-AGAGGTGGGGAGG 
 
                          
         B.   WEMSA 
                      Sp-1-like oligos        1           2                3             4 
                                                         
                      Calcitriol              -      +    -     +      -     +        -       + 
Sp-1 
Fig. 3: Sp-1 displays similar binding activity for both canonical
and candidate CD14 promoter Sp-1 DNA binding sequences.
Nuclear extract from calcitriol-treated and untreated THP-1 cells were used
for WEMSA analysis using non-labeled canonical (A) and (B) the candidate
CD14 promoter Sp-1 like oligo (sequence #4 from Fig. 1).
A.     WEMSA (Sp-1 canonical oligo) 
 
                                                        
 
 
 
                           B.   WEMSA (Sp-1-like oligo) 
 
                                                             
                
   Sp-1 
Cacitriol                   -                                    + 
Cacitriol              -                               + 
   Sp-1 33
cells (Figs. 3A and B).
Validation of WEMSA Analysis of Calcitriol-Regulated Sp-1
Binding to a Site in the CD14 Promoter by Classical EMSA
The analysis of calcitriol-regulated Sp-1 binding to this
site in the CD14 promoter using WEMSA suggested that
calcitriol negatively regulated Sp-1 binding to a specific
DNA sequence (Figs. 2 and 3). In order to validate the
results of WEMSA, we used the same candidate Sp-1-like
oligo (5'-AGAGGTGGGGAGG-3') in a classical EMSA.
THP-1 cells were treated with or without calcitriol and
nuclear extracts were prepared and incubated with this
Sp-1-like sequence. DNA-protein complexes were then
separated   by   polyacrylamide   gel   electropheresis   for
EMSA. The results shown in Fig. 4 clearly demonstrate
clacitriol-mediated down-regulation of Sp-1 binding to the
candidate Sp-1 binding sequence in the CD14 promoter,
thereby corroborating the results obtained by WEMSA.
Taken together, these results confirm that the  candidate
Sp-1-like binding site located at position -91 to -79 is a
bona fide site for Sp-1 binding and that calcitriol reduces
Sp-1 binding to this position in the CD14 promoter.
The broad applicability of WEMSA is demonstrated by its
use in identifying the involvement of Sp-1, and in an
earlier study, the transcription factor CREB, in calcitriol-
mediated  CD14  expression (6). This demonstrates that
WEMSA provides a suitable substitute for classical EMSA
as a method to directly detect the potential involvement of
transcription   factors   and   their   cognate   DNA  binding
elements in gene regulation. In addition, WEMSA offers
several advantages over classical EMSA which make this
technique   an   attractive   alternative   to   electrophoretic
mobility shift assays. WEMSA is highly cost effective as
compared to EMSA-based supershifts, as WEMSA does
not require the use  of modified oligonucleotides  and
antibodies can be used and recycled.
It is difficult to calculate the precise cost savings afforded
by   WEMSA  over   EMSA.   However,   our  best  estimate
would be  around 30%. This is based on the cost of
biotinylated oligonucleotides in EMSA as compared to
unlabelled oligonucleotides in WEMSA and recycling of
primary antibody in WEMSA as compared to EMSA.
Moreover, antibodies suitable for conducting supershift
assays in EMSA are often limited, as these are required to
recognize epitopes under native conditions. In WEMSA,
however, any antibody that is suitable for conventional
Western blotting can be used. Thus, WEMSA provides an
attractive option to classical EMSA as a method for the
identification of transcription factors and their cognate
DNA   binding   elements   involved   in   regulating   gene
expression.
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Fig. 4: EMSA analysis confirms results obtained through
WEMSA. EMSA using labeled Sp-1-like oligo spanning positions –91 to -79
of the CD14 promoter. Serum starved THP-1 cells were either untreated or
treated with 100 nM calcitriol for 30 min followed by preparation of nuclear
extracts for EMSA as described in Materials and Methods. Lane 1, free
labeled oligo. Lane 2, nuclear extract of untreated cells combined with
Sp-1-like oligo. Lane 3, nuclear extract of calcitriol-treated cells combined
with Sp-1-like oligo. Lane 4 represents nuclear extract from untreated cells
combined with Sp-1-like oligo and unlabelled excess of Sp-1-like oligo. 34
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PROTOCOLS
Western Blotting Electrophoresis Mobility Shift Assay (WEMSA) 
Reagents:
= Unlabelled and biotinylated Sp-1-like oligos for WEMSA and EMSA were from Invitrogen (Carlsbad, CA).
Unlabelled and biotinylated canonical Sp-1 oligos and EMSA kit (EMSA Gel-Shift Kit # AY 1288 P) were
purchased from Panomics (Fremont, CA). Anti-Sp-1 antibody was from Upstate Cell Signaling Solutions (Lake
Placid, NY) 
= The human promonocytic cell line THP-1 was from American Type Culture Collection, Rockville, MD 
= Cell culture medium: RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS), penicillin (100 units/ml) and streptomycin (100  g/ml). ￿  
= 1 , 25-dihydroxyvitamin D ￿ 3 (calcitriol) was obtained from Calbiochem (San Diego, CA). 
Methods: 
Nuclear extract: 
= Nuclear fractions were prepared based on a protocol from the Skirball Institute of Biomolecular Medicine,
NYU Medical Center with minor modifications (6). 
Non-denaturing PAGE:
= Prepare 5% non-denaturing polyacrylamide gels in Tris-borate/EDTA buffer (0.1 M Tris, 0.09 M boric acid
containing 1mM EDTA) and store at 4°C. 
= Mix 5-10  g of nuclear extracts from treated and control cells with relevant oligos and poly (dI-dC) (1  g/ l) in ￿ ￿ ￿
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binding buffer (20 mM HEPES pH 7.9, 1 mM DTT, 0.1 mM EDTA, 50 mM KCl, 5% glycerol and 200  g/ml ￿
BSA). 
= Add loading buffer to the above mixture to fractionate samples on gel at 4°C for 2-3 hrs using 100V. 
Western blotting:
= Transfer PAGE separated proteins onto nitrocellulose membrane using Western blotting semi-dry transfer
apparatus. 
= Block the membrane and probe with anti-Sp-1-antibody as per the manufacturer’s instructions (Upstate Cell
Signaling Solutions). 
= Develop with ECL system.
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